BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/21/2019 9:19:18 AM | Browse: 1016 | Download: 2072
 |
Received |
|
2019-05-09 01:18 |
|
Peer-Review Started |
|
2019-05-10 03:09 |
|
First Decision by Editorial Office Director |
|
2019-06-16 18:40 |
|
Return for Revision |
|
2019-06-17 07:06 |
|
Revised |
|
2019-07-09 09:38 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2019-07-12 10:13 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2019-07-19 15:24 |
|
Articles in Press |
|
2019-07-19 15:24 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2019-08-19 06:34 |
|
Publish the Manuscript Online |
|
2019-08-21 09:19 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Ustekinumab: ‘Real-world’ outcomes and potential predictors of nonresponse in treatment-refractory Crohn’s disease
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Peter Hoffmann, Johannes Krisam, Cyrill Wehling, Petra Kloeters-Plachky, Yvonne Leopold, Nina Belling and Annika Gauss |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Peter Hoffmann, MD, Doctor, Doctor, Gastroenterology and Hepatology, University Hospital Heidelberg, Im Neuenheimer Feld 410, Heidelberg 69120, Germany. peter.hoffmann@med.uni-heidelberg.de |
| Key Words |
real-world; ustekinumab; Crohn’s disease; NOD; ; |
| Core Tip |
Real-world data on ustekinumab in Crohn’s disease are scarce. This is a retrospective monocentric study. Patients with Crohn's disease who began ustekinumab therapy at a tertiary referral centre between 2016 and 2018 were included. The primary study endpoint was combined steroid-free clinical remission or response at 24 ± 6 wk of ustekinumab therapy. Fifty-seven patients were included in the study. Twenty patients (35.1%) achieved remission and 6 (10.5%) achieved a clinical response. Male sex, extraintestinal manifestations and the use of steroids at baseline were predictors of nonresponse to ustekinumab therapy. In a ‘real-world’ treatment-refractory cohort of patients with Crohn's disease, ustekinumab appeared efficacious and safe. |
| Publish Date |
2019-08-21 09:19 |
| Citation |
Hoffmann P, Krisam J, Wehling C, Kloeters-Plachky P, Leopold Y, Belling N, Gauss A. Ustekinumab: ‘Real-world’ outcomes and potential predictors of nonresponse in treatment-refractory Crohn’s disease. World J Gastroenterol 2019; 25(31): 4481-4492 |
| URL |
https://www.wjgnet.com/1007-9327/full/v25/i31/4481.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v25.i31.4481 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
